

(10) International Publication Number
WO 2012/166716 A3(43) International Publication Date
6 December 2012 (06.12.2012)

(51) International Patent Classification:

A61K 31/4178 (2006.01) A61P 31/12 (2006.01)
A61K 31/4164 (2006.01) A61P 31/00 (2006.01)

(21) International Application Number:

PCT/US2012/039835

(22) International Filing Date:

29 May 2012 (29.05.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/490,881 27 May 2011 (27.05.2011) US
61/504,905 6 July 2011 (06.07.2011) US
61/567,216 6 December 2011 (06.12.2011) US

(71) Applicant (for all designated States except US): **ACHIL-
LION PHARMACEUTICALS, INC.** [US/US]; 300
George Street, New Haven, Connecticut 06511 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WILES, Jason Allan**
[CA/US]; 33 James Street, Hamden, US 06518 (US).
WANG, Qiuping [US/US]; 79 Carriage Drive, Bethany,
Connecticut 06524 (US). **HASHIMOTO, Akihiro**
[JP/US]; 47 Laurel Street, Branford, Connecticut 06405
(US). **PAIS, Godwin** [IN/US]; 2 Kaye Plaza, Apt. E1,
Hamden, Connecticut 06514 (US). **CHEN, Dawei**
[CN/US]; 158 Saddle Hill Drive, Middletown, Connecticut
06457 (US). **WANG, Xiangzhu** [CN/US]; 2 Runnymede
Lane, Madison, Connecticut 06443 (US).
GADHACHANDA, Venkat [IN/US]; 5121 Town Walk
Dr., Hamden, Connecticut 06518 (US). **PHADKE,**
Avinash [IN/US]; 51 Gilbert Lane, Branford, Connecticut

06405 (US). **DESHPANDE, Milind** [US/US]; 44 Field
Brook Road, Madison, Connecticut 06443 (US).

(74) Agent: **MAXWELL, Leslie-Anne**; CANTOR COLBURN
LLP, 20 Church Street 22nd floor, Hartford, Connecticut
06103 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

[Continued on next page]

(54) Title: SUBSTITUTED ALIPHANES, CYCLOPHANES, HETERAPHANES, HETEROPHANES, HETERO-HETERAPHANES
AND METALLOCENES USEFUL FOR TREATING HCV INFECTIONS



(57) Abstract: The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula (I) D-M-D (Formula I) useful as antiviral agents. In certain embodiments disclosed herein M is a group -P-A-P- where A is (Formula I) Certain substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes disclosed herein are potent and/ or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions/ and combinations containing one or more substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes and a pharmaceutically acceptable carrier are also provided by this disclosure. Methods for treating viral infections, including Hepatitis C viral infections are provided by the disclosure.

**Published:****(88) Date of publication of the international search report:**

21 February 2013

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*